CNO Financial Group Third Quarter 2026 Earnings Results - CNO FINANCIAL GROUP INC

Explicit Guidance:

• Full-Year 2026 Operating EPS: Raised to a range of $5.05–$5.15 (midpoint up 9% from prior guidance).
• Full-Year 2026 Expense Ratio: Expected to be 18.6%–18.8% (improved from prior 18.8%–19.0%).
• Full-Year 2026 Effective Tax Rate: Estimated at ~20.5% (down from prior 21.5%).
• Full-Year 2026 Fee Income: Projected at ~$25 million, driven by the shift from Medicare Advantage to Medicare Supplement.
• Full-Year 2026 Free Cash Flow: Expected range of $220 million–$240 million.
• Capital & Liquidity: No changes to target RBC ratio, minimum holding company liquidity, or leverage ranges.
• ROE Target: 2026 operating ROE expected to exceed the 12% target originally set for year-end 2027.
• Long-Term Planning: New long-term performance targets to be established in February 2027.
• 2027 Capital Spend: Technology modernization ("TechMod") cash spend expected to be comparable to 2026 levels (~$70 million full-year run rate).

Business-Segment Outlook:

• Medicare Supplement: Anticipates continued strong growth and a secular shift in consumer preference from Medicare Advantage (MA) to Supplement due to MA market disruptions (carriers exiting, reducing benefits). Medicare Supplement NAP increased 41% QoQ and >60% over 12 months; Medicare Advantage enrollment is creating a "dislocation" benefiting agents.
• Life Insurance: Life NAP growth remains strong when excluding discontinued third-party pilot programs (up 20% organically). Direct-to-consumer NAP grew 29%.
• Annuities: Fixed Indexed Annuities (FIA) expected to benefit from growth in the block and favorable go-forward income patterns. New money rates remain above 6% (6.24% in Q3), supporting durable investment income generation.
• Worksite Division: Sustained double-digit sales growth (8th consecutive quarter); focus on small-to-mid-sized businesses and employer-paid voluntary benefits to manage healthcare costs.
• Brokerage/Advisory: Client assets and accounts growing at record rates; combined with annuity values, total client assets exceed $20 billion (up 9%).
• Bermuda Operations: Following the third reinsurance transaction, focus shifts in 2027 to optimizing assets and capital across diversified liabilities (annuity, health, life). Aims to settle into a "run rate cadence" by 2028 and beyond.

Market and Competitive Outlook:

• Demand Trends: Demand for core products is expected to remain "relatively robust" through 2027, driven by demographic shifts (65+ population growth) and lack of employer-provided alternatives for middle-income consumers.
• Competitive Moat: The "last mile captive agent" distribution model and focus on advisory relationships (vs. price-shopping) are positioned to capture market share during Medicare Advantage dislocations.
• Pricing/Underwriting: Morbidity and mortality experience have been favorable overall, though Medicare Supplement morbidity remains elevated; new actuarial assumptions reflect higher near-term claims but anticipate future reserve releases.
• Investment Market: Continued ability to invest in high-quality names at attractive yields; portfolio remains high-quality with flexibility across market environments.

Macro / Industry Outlook:

• Economic Sensitivity: Management views the business as largely "immune" to near-term macroeconomic headwinds (gas prices, inflation, interest rates) due to the essential nature of retirement and Medicare needs for the middle-income demographic.
• Regulatory Environment: Bermuda operations benefit from a strong regulatory framework; continued collaboration with U.S. and Bermuda regulators regarding capital optimization.
• Interest Rates: New money rates exceeding 6% for 15 consecutive quarters support investment income growth.

Strategic Initiatives:

• Reinsurance Transactions: Third treaty effective October 1, 2026, seeding $270 million of U.S. statutory graded benefit life reserves (Colonial Penn) to the Bermuda affiliate. This is viewed as the final major in-force seeding; no further material in-force blocks expected in the near term.
• Capital Optimization: 2027 focus on deploying excess capital in Bermuda efficiently; specific initiatives subject to regulatory approval.
• Technology Investment: Ongoing modernization spend of ~$70 million in 2026, with 2027 spending anticipated to match.
• Share Returns: Continued capital deployment via share repurchases (4% reduction in shares outstanding in Q3) and dividends.
• Product Mix: Strategic emphasis on diversifying product portfolio based on customer needs rather than single products, particularly expanding the total households served via Medicare as a "door opener."

Risks and Headwinds to Outlook:

• Actuarial Assumptions: Potential for reversion to the mean regarding favorable insurance product margin experience (recent "puts" may balance out future "takes").
• Unallocated NII: Recent net investment income outperformance (~$12 million above estimate) attributed to favorable alternative investments is not expected to continue.
• Market Dislocation: While current MA disruptions are beneficial, a potential reversion in the shift from MA to Supplement could impact sales momentum.
• Macroeconomic Pressure: While deemed less sensitive, management acknowledges that higher expenses could marginally influence consumer decisions for those "close to deciding" on purchases.
• Regulatory Approval: Future Bermuda capital optimization activities are contingent upon approval from U.S. and Bermuda regulators.

Management Tone on the Future:

• Confidence Level: High; described performance as "excellent," "consistent," and "repeatable." Management expressed confidence in ending the year strong and achieving top-quartile ROE performance.
• Strategic Clarity: Clear articulation of the "flywheel" picking up momentum regarding ROE improvement.
• Guidance Changes: Raised EPS guidance and free cash flow guidance (tighter range, slightly lower high-end) reflecting strong Q3 and disciplined capital management.
• Hedges/Qualifiers: Standard forward-looking statement warnings included; acknowledgment that specific investment income spikes will normalize.

Miscellaneous:

• Investment Portfolio: ~$2 billion in private credit total (approx. half in ABS/Private Credit Funds); highly structured, investment-grade, short-duration, and protected against binary risk.
• Expense Ratio: Current run rate considered sustainable with potential for further improvement via operating leverage as business grows.
• Capital Position: Robust, with liquidity and capital metrics within or above target levels, allowing for organic growth, investment, and shareholder returns.